YOLFTbeta
00

JW Pharmaceutical Corp

001067 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

48,400.00KRW-100.00 (-0.21%)

Price History

Full chart

Market Stats

Previous Close48,500.00
Open47,700.00
Day Range47,700.00 – 48,400.00
52-Week Range38,500.00 – 60,786.16
Volume26
Market Cap1.14T
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield1.30%
Beta1.02
50-Day Avg46,667.00
200-Day Avg52,193.25

About

JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is based in Gwacheon-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Young-Sub Shin
  • Employees1.05K
  • HeadquartersJW Gwacheon Tower, 38, Gwacheon-si, South Korea, 13840, Korea
  • Websitehttps://www.jw-pharma.co.kr

Leadership

  • Mr. Young-Sub ShinCEO, Head of Sales & Marketing and Inside Director · b. 1963
  • Sung-Yeol LeeCEO, Head of Product Development & Management and Director
  • Jae-Kwang JeonHead Managing Director and Head of Public Relation · b. 1962
  • Mr. Hyun-seok HanHead of Product Plant · b. 1962
  • Kim Yong KwanDevelopment Head & Internal Director

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue412.79B434.35B467.47B502.92B537.18B511.34B547.34B606.58B684.35B748.53B719.38B775.30B
Growth (%)-+5.22%+7.62%+7.58%+6.81%-4.81%+7.04%+10.83%+12.82%+9.38%-3.89%+7.77%
Cost of Revenue261.52B273.73B294.12B314.29B340.14B350.22B369.81B372.21B396.40B412.98B395.88B415.98B
Gross Profit151.27B160.62B173.34B188.63B197.04B161.12B177.53B234.38B287.95B335.54B323.50B359.31B
Gross Margin36.65%36.98%37.08%37.51%36.68%31.51%32.43%38.64%42.08%44.83%44.97%46.35%
Operating Expense138.04B139.10B148.81B166.91B175.46B180.13B178.85B203.18B225.18B234.63B240.77B264.85B
Operating Income13.23B21.52B24.54B21.72B21.58B-19.01B-1.32B31.20B62.78B100.92B82.73B94.46B
Operating Margin3.21%4.96%5.25%4.32%4.02%-3.72%-0.24%5.14%9.17%13.48%11.50%12.18%
EBITDA---26.32B36.60B-2.71B15.07B43.98B71.59B89.97B111.55B112.01B
EBITDA Margin---5.23%6.81%-0.53%2.75%7.25%10.46%12.02%15.51%14.45%
Net Income-2.36B1.96B-10.93B-742.47M8.06B-25.28B-15.24B-967.85M31.89B37.01B65.04B61.51B
Net Income Margin-0.57%0.45%-2.34%-0.15%1.50%-4.94%-2.78%-0.16%4.66%4.94%9.04%7.93%
R&D17.48B16.48B18.00B21.98B21.27B25.22B22.94B19.88B33.74B33.67B36.24B45.45B
R&D as % of Total Revenue4.24%3.79%3.85%4.37%3.96%4.93%4.19%3.28%4.93%4.50%5.04%5.86%
Interest Expense00008.69B11.28B7.59B7.34B9.39B12.56B10.03B4.42B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%1.62%2.21%1.39%1.21%1.37%1.68%1.39%0.57%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets589.24B613.48B651.08B630.87B593.79B573.21B549.09B633.05B627.97B645.04B604.60B605.27B
Total Liabilities369.22B388.07B374.76B360.10B333.68B343.12B341.62B444.51B402.21B379.60B275.11B235.90B
Total Equity216.15B224.83B276.31B270.78B260.11B230.08B207.49B201.19B240.35B265.44B329.49B369.37B
Cash4.97B8.18B39.25B32.10B30.95B41.86B10.45B33.37B33.90B15.91B10.43B39.23B
Net Debt---158.26B144.27B143.27B169.60B209.18B172.54B127.23B56.07B-

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow7.28B-4.17B6.74B33.45B52.11B55.53B63.05B18.12B56.76B87.16B79.39B96.40B
Investing Cash Flow10.82B-7.35B-8.77B-9.89B-13.92B-21.98B-79.43B-22.87B-18.92B---
Financing Cash Flow-14.07B14.68B33.83B-27.87B-41.19B-24.16B-14.01B27.20B-36.91B---
Capital Expenditure6.93B5.56B10.02B7.50B8.64B9.28B12.39B7.47B9.92B40.71B28.14B36.12B
Free Cash Flow---22.50B43.76B42.43B48.02B5.22B44.41B46.45B51.25B60.28B
Dividends Paid1.75B2.69B2.71B5.88B6.51B6.82B6.95B7.15B7.35B8.81B9.67B11.07B
FCF to OCF---67.26%83.99%76.42%76.15%28.81%78.24%53.30%64.56%62.53%
Dividend Paid to FCF---26.15%14.88%16.06%14.48%136.90%16.55%18.97%18.86%18.36%

Key Statistics & Ratios

Market Cap1.14T
Enterprise Value589.58B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.39
Price / Book2.83
Revenue (TTM)820.86B
Gross Profit (TTM)388.22B
EBITDA127.31B
Profit Margin12.34%
Operating Margin15.02%
Return on Equity27.63%
Return on Assets10.78%
Shares Outstanding206.75K
Shares Float11.60M
Beta1.02
Dividend Yield1.30%
Dividend Rate650.00
Payout Ratio15.53%

Dividends

20261×
650.00Mar 31, 2026
20241×
450.00Dec 27, 2024
20231×
400.00Dec 27, 2023
20221×
356.94Dec 28, 2022
20211×
309.35Dec 29, 2021
20201×
291.59Dec 29, 2020
20191×
291.59Dec 27, 2019
20181×
291.59Dec 27, 2018
20171×
246.73Dec 27, 2017
20161×
219.90Dec 28, 2016
20151×
123.19Dec 29, 2015
20141×
97.77Dec 29, 2014
20131×
97.77Dec 27, 2013
20121×
111.74Dec 27, 2012
20111×
762.66Dec 28, 2011
20101×
1089.51Dec 29, 2010
20091×
196.80Dec 29, 2009
20081×
191.07Dec 29, 2008
20071×
185.50Dec 27, 2007
20061×
82.45Dec 27, 2006
20051×
80.04Dec 28, 2005
20041×
112.06Dec 29, 2004
20031×
104.06Dec 29, 2003
20021×
64.04Dec 27, 2002

Stock Splits

  • Dec 27, 20231.02:1
  • Mar 13, 20231.03:1
  • Dec 29, 20211.03:1
  • Dec 29, 20201.03:1
  • Dec 27, 20171.02:1
  • Dec 28, 20161.02:1
  • Dec 29, 20151.05:1
  • Dec 29, 20141.05:1
  • Dec 27, 20131.05:1
  • Dec 27, 20121.05:1
  • Oct 4, 20120.186:1
  • Dec 28, 20111.05:1
  • Dec 29, 20091.03:1
  • Dec 29, 20081.03:1
  • Apr 16, 20082:1
  • Jul 2, 20070.637:1